Comparing the current results to its competitors, Aeon Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.28 %, recorded in the same quarter.
Aeon Biopharma inc , slower than the average decrease reported by the company's competitors of -54.63 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -54.63 %
Aeon Biopharma Inc 's Comment on Competition and Industry Peers
The competitive landscape for botulinum toxin products includes Daewoong, which produces ABP-450 and Jeuveau®. Jeuveau® is marketed by Evolus for aesthetic use. ABP-450, approved in over 69 countries, has demonstrated non-inferiority to Botox® in cosmetic indications. Other competitors include Dysport® and Xeomin®, which differ from Botox® in molecular weight and clinical administration. The company focuses exclusively on therapeutic indications for ABP-450, which it considers a competitive advantage. Market competitors typically obtain an original Biologics License Application (BLA) for initial indications and supplemental BLAs for expanded uses, influencing pricing dynamics between cosmetic and therapeutic applications.
May 9, 2024
AEON Biopharma, a prominent name in the pharmaceutical sector, recently provided an update concerning its diverse development pipeline. The update explicitly outlines four significant clinical programs, bifurcated into two late-stage and two early-stage initiatives.The two late-stage clinical programs offer the cornerstone of this announcement. As these are at a mature stage in the research and testing phase, data generated from these projects could potentially hold significant implications for the company and the industry alike. However, it remains crucial to note that late-stage clinical trials, while promising, are also a high-stake phase where the potential for both pivotal breakthroughs and challenges i...
January 18, 2024
In a groundbreaking presentation at a premier neurotoxin conference, AEON Biopharma unveiled positive clinical and pre-clinical data for their latest development, ABP-450 (prabotulinumtoxinA). The results showcased the remarkable potential of this innovative treatment in effectively addressing two debilitating conditions - cervical dystonia (CD) and post-traumatic stress disorder (PTSD).The open-label extension (OLE) Phase 2 data presented at the conference revealed that ABP-450 achieved its peak efficacy in treating CD within an impressively short timeframe of just four weeks. Beyond this initial period, the durability of the treatment s effect was demonstrated to last for an extended period of 12 to 16 wee...
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Kiniksa Pharmaceuticals International Plc Share Performance
+107.30%
One Year
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Sources:
Aeon Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aeon Biopharma inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
